Sanofi's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sanofi (SNY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sanofi vs Its Competitors
- TTM: Trailing 12-month revenue of 49,308M vs 781,825M combined for its competitors (5.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+324.4% annualized vs trailing 12 months), vs accelerating (+64.0%) for its tracked peer group.
- Growth: Sanofi generated 5.5% revenue growth year over year in Q4 2025, vs 12.6% for its competitors combined.
- Profitability: Its 16.8% net margin compares with 16.0% for the peer group.
- Scale: Sanofi ranks #13 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 1.9% of industry market cap.
- Peer revenue share: Sanofi accounted for 14.0% of combined revenue among its tracked peer group, down from 14.8% a year earlier.
- Peer differentiation: Revenue per employee of $21.61M compares with $0.92M for the peer group (23.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SNY Sales vs. its Competitors, Q4 2025
Sanofi reported revenue growth of 5.49 % year on year in Q4 2025, below its competitors' combined revenue growth of 12.63 %.
With a net margin of 16.81 %, Sanofi achieved higher profitability than its competitors (16.00 %).
Sanofi generated 14.03 % of the combined sales of its peer group, down from 14.84 % a year earlier.
Sanofi vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Sanofi reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sanofi and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sanofi | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (57) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sanofi's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 5.5% for Sanofi. Sanofi's share of combined industry revenue moved from 10.32% to 10.00%, a loss of 0.32 percentage points.
Sanofi's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sanofi | Yes | Yes | Yes | No |
| Competitors combined (186) | ||||
| High-Confidence Competitors (70) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SNY Stock Performance relative to its Competitors
SNY Stock Performance relative to High-Confidence Competitors
SNY Stock Performance relative to Similar-Size Competitors
SNY Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 3 | Chimerix Inc | 282.9% | Outperformed |
| 4 | Gt Biopharma Inc | 282.9% | Outperformed |
| 5 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sanofi's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sanofi's Comment on Competition and Industry Peers
Publicly Traded Peers of Sanofi
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Sanofi |
57,492.90 | 49,307.90 |
 Eli Lilly And Company |
1,221,912.11 | 86,462.00 |
 Johnson and Johnson |
666,802.75 | 99,335.00 |
 Beone Medicines Ltd |
582,951.40 | 6,128.24 |
 Abbvie Inc |
510,761.28 | 66,014.00 |
 Merck and Co Inc |
362,843.00 | 66,569.00 |
| SUBTOTAL | 5,608,705.85 | 861,748.19 |
Sign in to see all competitors of Sanofi.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sanofi versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sanofi's Competitors Named by the Company
Competitive relationships identified from Sanofi reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Petvivo Holdings Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Anika Therapeutics Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Cingulate Inc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Scilex Holding Company | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Protalix Biotherapeutics inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Semnur Pharmaceuticals Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Quantum Biopharma Ltd | Company report | 85% |
| Absci Corp | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Evolus Inc | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Biontech Se | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Medicenna Therapeutics Corp. | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| CVS/Caremark | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Biolinerx Ltd | Company report | 85% |
| Express Scripts | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| OptumRx | Company report | 85% |
| Geovax Labs Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Prestige Consumer Healthcare Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Vivani Medical Inc | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Optinose Inc | Company report | 85% |
| Zyversa Therapeutics Inc | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Vbi Vaccines Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Organon and Co | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Amicus Therapeutics inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Valneva Se | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Spero Therapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sanofi's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Sanofi's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sanofi's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sanofi | 57,493 | 21,607,316 | 3,889,794 |
| Eli Lilly And Company | 1,221,912 | 1,729,240 | 551,594 |
| Johnson and Johnson | 666,803 | 705,504 | 114,311 |
| Beone Medicines Ltd | 582,951 | 510,686 | 54,642 |
| Abbvie Inc | 510,761 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,843 | 887,587 | 42,267 |
| PEERS TOTAL | 5,551,213 | 918,885 | 115,462 |
Sanofi's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sanofi's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Sanofi's industry classification, broader than the peer set above. Market cap in millions of $.Sanofi ranks #13 of 496 companies by market capitalization in its industry, holding 1.94 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 13 | Sanofi | 116,015 | 1.94 % |
Market cap and industry share for the rest of Sanofi's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Sanofi's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 8 | Novo Nordisk A | 182,315 | -15.12 % |
| 9 | Pfizer Inc | 177,495 | 28.17 % |
| 10 | Astrazeneca Plc | 149,273 | 17.71 % |
| 11 | Vertex Pharmaceuticals Inc | 140,784 | 30.83 % |
| 12 | Bristol myers Squibb Company | 1,234 | 12.3% |
| 13 | Sanofi | 116,015 | -3.62 % |
| 14 | Gsk Plc | 1,234 | 12.3% |
| 15 | Regeneron Pharmaceuticals Inc | 1,234 | 12.3% |
| 16 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
| 17 | Royalty Pharma Plc | 1,234 | 12.3% |
| 18 | Zoetis Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Sanofi's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Sanofi's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 76.47 % | 37.69 % (avg) | +38.8 pp |
| Operating Margin | 14.55 % | industry median | +10.3 pp |
| EBITDA Margin | 11.41 % | -6.49 % (avg) | +17.9 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.58 % (avg) | -7.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sanofi's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 7.8x | 26.6x | -18.8x |
| EV / EBITDA | 23.0x | 15.9x | +7.0x |
| P/B | 1.4x | 4.3x | -2.8x |
| Return on Equity | 10.55 % | industry aggregate | -9.57 % |
| Return on Invested Capital | 3.72 % | -9.93 % (avg) | 13.65 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sanofi's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 2.63 % | 9.00 % | 10.93 % |
| Operating Margin | 18.46 % | 17.65 % | 14.55 % |
| Return on Invested Capital | 3.56 % | 4.26 % | 3.72 % |
| P/E | 11.4x | 11.5x | 7.8x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sanofi's Strategic Group Map
Sanofi is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Sanofi's trailing-12-month revenue growth of 10.9% and operating margin of 14.6% compares with an average of 10.2% growth and 12.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Sanofi sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Sanofi's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Sanofi falls in the Dog quadrant: relative market share of 0.09x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Sanofi's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Sanofi's dedicated Suppliers and Customers pages, not here.
Sanofi's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Sanofi falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sanofi's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 10.3 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+324.4% annualized vs trailing 12 months).
Weaknesses
- Return on equity 9.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.09x).
Opportunities
- Trades at a lower P/E than the industry average (7.8x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (47.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Sanofi's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sanofi | 0.27 | 1.09 | 0.20 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sanofi's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sanofi | Q4 2025 | +10.9 % | +46.0 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.0 % | +6.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sanofi's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sanofi | Q4 2025 | +9.3 % | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sanofi's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sanofi | 5.96% | 8.19% | 10.55% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sanofi's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sanofi | 7.36 | 1.17 |
| Eli Lilly And Company | 44.41 | 14.13 |
| Johnson and Johnson | 41.20 | 6.71 |
| Beone Medicines Ltd | 880.11 | 95.13 |
| Abbvie Inc | 49.61 | 7.74 |
| Merck and Co Inc | 118.47 | 5.45 |
| PEERS AVERAGE | 50.55 | 6.51 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.